Skip to main content
OpenTrials
Recruiting

NCT Number: NCT04847284

Intraoperative Radiotherapy in Patients With Brain Metastases

Intraoperative radiotherapy (IORT) is a new alternative for local radiotherapy with the advantages of dose escalation, reduced overall treatment time, and enhanced patient convenience, however the degree of efficacy is unknown, as well as and which is the most efficient dose.

The objective of this study is to evaluate the efficacy and safety of IORT in patients with surgical excision of brain metastases at a dose of 20 Gy is at least as effective and safe as other forms of radiation therapy in patients with resection of brain metastases.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Hospital del Mar

Barcelona, 08003, Spain

Location status: Recruiting

Location contact

Gloria Villalba, MD, PhD

PRINCIPAL_INVESTIGATOR

Palmira Foro Arnalot, MD, PhD

CONTACT

[email protected]

93248357

Palmira Foro Arnalot, MD, PhD

PRINCIPAL_INVESTIGATOR

About this study

  • INTRODUCTION

Brain metastases occur in roughly 30% of all cancer patients during their course of disease. Their incidence is believed to rise due to the aging population that develops more cancer per se, an increase in overall survival due to more effective extracranial therapies but with only few (novel) substances crossing the blood-brain barrier and more broadly available and more advanced imaging techniques.

Neurosurgical treatment remains a cornerstone in the management of brain metastasis, especially for lesions causing mass effects or neurological deficits or in case tissue is necessary to establish a diagnosis. As local recurrence rates are as high as 50-60% after surgical resection alone, adjuvant therapies to prevent such are necessary.

Whole brain radiotherapy (WBRT) does not influence survival but rather impairs neurocognitive functions and, as histologic in-depth exams of cavity borders showed that most brain metastases infiltrate only 0.3-1.2 mm into the surrounding healthy brain tissue, therefore treatment is to date usually confined to the cavity margin. Thus, the currently recommended standard of care is post-operative stereotactic radiosurgery (SRS) to the resection cavity. One of the drawbacks of this modality is the incidence of radionecrosis, especially in large tumor volumes. As an alternative to radiosurgery, hypofractionated local radiotherapy is also used, reducing the risk of radionecrosis in large volumes. There are no prospective randomized studies comparing both techniques.

The need to find a modality of radiotherapy that achieves al least the efficacy of radiosurgery or hypofractionated local radiotherapy, without the disadvantages thereof, makes IORT as a possible treatment alternative.

The objective of this study is to evaluate the efficacy and safety of IORT in patients with surgical excision of brain metastases at a dose of 20 Gy is at least as effective and safe as other forms of radiation therapy in patients with resection of brain metastases.

  • OBJECTIVES

Primary Objective

  • Median local progression free survival (lPFS), defined as time span (in months) between surgery and recurrence within a 0,5 cm margin around the resection cavity, assessed by serial MRI scans and RANO response assessment criteria for brain metastases .
  • Radiation-related (acute / late) neurotoxicity, assessed by regular neurological examinations and serial MRI scans.

Secondary objectives

  • Median regional PFS (rPFS), resembling the time (in months) from surgery to any progression outside of the 0,5 cm margin around the resection cavity, assessed by serial MRI scans and RANO response assessment criteria for brain metastases .
  • Global PFS (gPFS), defined as the time (in months) from surgery to any intra- and extracranial tumor progress.
  • Median overall survival (OS), defined as the time (in months) from surgery of brain metastases to death from by any cause.
  • DESIGN

This trial is an open, single arm, single institution, prospective trial to determine the efficiency and safety of IORT with low-energy photons to the cavity after resection of brain metastases. A total of 25 patients will be included.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age ≥ 18 years
  • Karnofsky Performance Status ≥ 70
  • Newly diagnosed cerebral or cerebellar lesion (contrast enhancing on a T1-weighted MRI scan) amenable to total resection with no dural attachment
  • Frozen section confirming a metastasis of an extracranial ( Central Nervous System i.e. non-CNS) tumor
  • Adequate distance to optic nerve(s), chiasm and brainstem (organs at risk for radiotherapy)
  • Adequate birth control

Exclusion criteria

  • Leptomeningeal spread and dural attachment (assessed pre- and intraoperatively)
  • Frozen section reveals primary CNS tumor, lymphoma, SCLC (Small-cell lung cancer) or germinoma
  • More than one brain metastasis
  • Psychiatric or social condition potentially interfering with compliance
  • Contraindication against anesthesia, surgery, MRI and/or contrast agents
  • Pregnant or breast-feeding women

Treatment and study plan

intraoperative radiotherapy

Radiation

Intraoperative radiotherapy application immediately following resection of brain metastases.

Primary outcomes

  1. Median local progression free survival (lPFS)

    Time frame: 6 months from the date of surgery.

    Recurrence within a 0.5 cm margin around the resection cavity, assessed by serial magnetic resonance imaging (MRI scans) and response assessment criteria in neuro-oncology (RANO)

  2. Radiation-related acute neurotoxicity

    Time frame: 3 months from the date of surgery.

    Neurotoxicity related to radiotherapy evaluated according to the scale of the Common Terminology Criteria for Adverse Events (CTCAE) version 5. Score from 0 to 5, with 5 being the worst toxicity

    • Acute toxicity: cerebral edema
  3. Radiation-related late neurotoxicity

    Time frame: 6 months from the date of surgery.

    Neurotoxicity related to radiotherapy evaluated according to the scale of the Common Terminology Criteria for Adverse Events (CTCAE) version 5. Score from 0 to 5, with 5 being the worst toxicity

    • Late toxicity: radionecrosis.

Secondary outcomes

  1. Median regional PFS (rPFS)

    Time frame: 6 months from the date of surgery

    To any progression outside of the 0.5 cm margin around the resection cavity, assessed by serial MRI scans and RANO response assessment in neuro-oncology .

  2. Global PFS (gPFS)

    Time frame: 6 months from the date of surgery

    The time (in months) from surgery to any intra- and extracranial tumor progress

  3. Median overall survival (OS)

    Time frame: 6 months from the date of surgery

    The time (in months) from surgery of brain metastases to death from by any cause.

Study contacts

Contact information is provided by the study sponsor or research team.

Palmira Foro, MD, PhD

CONTACT

[email protected]

628118443

Palmira Foro, MD,PhD

CONTACT

[email protected]

628118443

Sponsors and collaborators

Lead sponsor

Parc de Salut Mar

Other

Registry information

Important dates

Study start
2021
Primary completion
2025
Study completion
2025
First posted
Apr 19, 2021
Registry last updated
Jun 6, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.